RE: If you were to have gyno surgery?
Gynecomastia is the benign growth of glandular tissue of the male breast. Among AAS using individuals, it is caused by the peripheral aromatization of androgens into estrogens. The increase in circulating estrogens causes proliferation of breast tissue cells and subsequent enlargement of the breast mass.
It should be suggested to the patient exhibiting severe gynecomastia that replacing aromatizable androgens such as the testosterone esters with a non-aromatizable androgen will reduce this particular side effect. Care should be taken however to monitor cholesterol levels should a switch be made to non-aromatizable androgens as they are known to negatively effect cholesterol levels.
Non-surgical: Nearly all of the auxiliary drugs taken by AAS using individuals to combat side effects, will be anti-estrogenic compounds. It is important for the physician to be aware of any additional drugs a patient may be taking in order not to overdose the patient.
Drug management therapies for gynecomastia involve reducing estrogen activity by either blocking the estrogen receptor and/or inhibiting peripheral aromatization of androgens. Tamoxifen citrate (Nolvadex) and Clomiphene citrate (Clomid) are suggested for competitive inhibition of estrogenic activity at the estrogen receptors, while Anastrozole (Arimidex) is suggested for aromatase inhibition.
Surgical: The surgical treatment for gynecomastia has had variations since 1538, when the first description of the surgical treatment was attributed to Paulus Aegineta. Since then, various incisions on and under the breast have been used. It is suggested that when gynecomastia is severe, the excess skin should be removed along with the gland and fat. Surgical treatment usually results in permenant resolution of gynecomastia, however, if some breast tissue is unknowingly missed, symptoms can return if high dose AAS use continues
Bench Press -200kg for 1
Dumbell Seated Press -2 x 60kg for 6